File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions

TitleChronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions
Authors
KeywordsALT
Chronic hepatitis B (CHB)
HBV DNA
Hepatitis B virus (HBV)
Interferon alfa
Nucleoside/nucleotide analog
Issue Date2010
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
Hepatology International, 2010, v. 4 n. 1, p. 386-395 How to Cite?
AbstractRecent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration. © 2010 Asian Pacific Association for the Study of the Liver.
Persistent Identifierhttp://hdl.handle.net/10722/144957
ISSN
2014 Impact Factor: 1.780
2014 SCImago Journal Rankings: 0.609
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Bristol-Myers Squibb
Funding Information:

Bristol-Myers Squibb provided an unrestricted educational grant to accredited medical education provider, Adrenalin Strategics (Australia), for management of the APPROACH Working Group meeting. Editorial support for the development of this report was provided by Adrenalin Strategics (Australia) and MediTech Media (Singapore).

References

 

DC FieldValueLanguage
dc.contributor.authorAhn, SHen_HK
dc.contributor.authorChan, HLYen_HK
dc.contributor.authorChen, PJen_HK
dc.contributor.authorCheng, Jen_HK
dc.contributor.authorGoenka, MKen_HK
dc.contributor.authorHou, Jen_HK
dc.contributor.authorLim, SGen_HK
dc.contributor.authorOmata, Men_HK
dc.contributor.authorPiratvisuth, Ten_HK
dc.contributor.authorXie, Qen_HK
dc.contributor.authorYim, HJen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorthe APPROACH Working Group-
dc.date.accessioned2012-02-21T05:44:53Z-
dc.date.available2012-02-21T05:44:53Z-
dc.date.issued2010en_HK
dc.identifier.citationHepatology International, 2010, v. 4 n. 1, p. 386-395en_HK
dc.identifier.issn1936-0533en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144957-
dc.description.abstractRecent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration. © 2010 Asian Pacific Association for the Study of the Liver.en_HK
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0en_HK
dc.relation.ispartofHepatology Internationalen_HK
dc.rightsAsian Pacific Association for the Study of the Liveren_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong Licenseen_US
dc.subjectALTen_HK
dc.subjectChronic hepatitis B (CHB)en_HK
dc.subjectHBV DNAen_HK
dc.subjectHepatitis B virus (HBV)en_HK
dc.subjectInterferon alfaen_HK
dc.subjectNucleoside/nucleotide analogen_HK
dc.titleChronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directionsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4551/resserv?sid=springerlink&genre=article&atitle=Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions&title=Hepatology International&issn=19360533&date=2010-03-01&volume=4&issue=1& spage=386&authors=Sang Hoon Ahn, Henry L. Y. Chan, Pei-Jer Chen, <i>et al.</i>en_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1007/s12072-010-9163-9en_HK
dc.identifier.pmid20305758-
dc.identifier.pmcidPMC2836441-
dc.identifier.scopuseid_2-s2.0-77949655951en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77949655951&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume4en_HK
dc.identifier.issue1en_HK
dc.identifier.spage386en_HK
dc.identifier.epage395en_HK
dc.identifier.eissn1936-0541en_US
dc.identifier.isiWOS:000275456400003-
dc.publisher.placeUnited Statesen_HK
dc.description.otherSpringer Open Choice, 21 Feb 2012en_US
dc.identifier.scopusauthoridAhn, SH=7401989551en_HK
dc.identifier.scopusauthoridChan, HLY=16038785900en_HK
dc.identifier.scopusauthoridChen, PJ=7408354514en_HK
dc.identifier.scopusauthoridCheng, J=34976376600en_HK
dc.identifier.scopusauthoridGoenka, MK=7006028553en_HK
dc.identifier.scopusauthoridHou, J=7401966390en_HK
dc.identifier.scopusauthoridLim, SG=7404081127en_HK
dc.identifier.scopusauthoridOmata, M=36043368300en_HK
dc.identifier.scopusauthoridPiratvisuth, T=6603268498en_HK
dc.identifier.scopusauthoridXie, Q=7201448360en_HK
dc.identifier.scopusauthoridYim, HJ=7005664934en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.citeulike6802838-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats